Comparison of Immune Responses to Two Quadrivalent Meningococcal Conjugate Vaccines (CRM197 and Diphtheria Toxoid) in Healthy Adults
10.3346/jkms.2019.34.e169
- Author:
Han Wool KIM
1
;
Soyoung LEE
;
Ji Hyen LEE
;
So Youn WOO
;
Kyung Hyo KIM
Author Information
1. Department of Pediatrics, Ewha Womans University College of Medicine, Seoul, Korea. kaykim@ewha.ac.kr
- Publication Type:Original Article
- Keywords:
Immunogenicity;
Meningococcal Vaccines;
Adult
- MeSH:
Adult;
Complement System Proteins;
Diphtheria;
Humans;
Immunization;
Information Services;
Korea;
Meningococcal Vaccines;
Military Personnel;
Serogroup;
Vaccination;
Vaccines;
Vaccines, Conjugate
- From:Journal of Korean Medical Science
2019;34(23):e169-
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: After the introduction of the meningococcal ACWY-CRM197 conjugate vaccine (MenACWY-CRM) in 2012 and the meningococcal ACWY-diphtheria toxoid conjugate vaccine (MenACWY-DT) in 2014, immunization was recommended for certain high-risk groups including new military recruits in Korea. However, comparative immunogenicity studies for these vaccines have not been performed in Korea. Here, we compared the immunogenicity of these two vaccines in healthy adults. METHODS: A total of 64 adults, 20–49 years of age, were randomly divided into two groups (1:1) to receive either of the two vaccines. The sera were obtained before and 1 month after vaccination and tested for serogroup-specific serum bactericidal activity using baby rabbit complement. RESULTS: There were no significant differences post-vaccination in the geometric mean indices and the seropositive rate to all serogroups between the vaccines. The proportion of seropositive subjects after vaccination ranged from 88% to 100%. CONCLUSION: Both meningococcal conjugate vaccines showed good immunogenicity in healthy Korean adults without statistically significant differences. Further investigations for serotype distribution of circulating meningococci and the immune interference between other diphtheria toxin-containing vaccines concomitantly used for military recruits are needed to optimize immunization policies. TRIAL REGISTRATION: Clinical Research Information Service Identifier: KCT0002460
